Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0000315066-15-002590
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-05-07 16:49:56
Reporting Period:
2015-05-05
Filing Date:
2015-05-07
Accepted Time:
2015-05-07 16:49:56
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1597264 Blueprint Medicines Corp BPMC Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
315066 Fmr Llc 245 Summer Street
Boston MA 02210
No No Yes Yes
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2015-05-05 1,818,181 $0.00 1,818,181 No 4 C Indirect Beacon Bioventures Fund III Limited Partnership
Common Stock Acquisiton 2015-05-05 469,696 $0.00 2,287,877 No 4 C Indirect Beacon Bioventures Fund III Limited Partnership
Common Stock Acquisiton 2015-05-05 87,834 $0.00 2,375,711 No 4 C Indirect Beacon Bioventures Fund III Limited Partnership
Common Stock Acquisiton 2015-05-05 125,000 $18.00 2,500,711 No 4 P Indirect Beacon Bioventures Fund III Limited Partnership
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect Beacon Bioventures Fund III Limited Partnership
No 4 C Indirect Beacon Bioventures Fund III Limited Partnership
No 4 C Indirect Beacon Bioventures Fund III Limited Partnership
No 4 P Indirect Beacon Bioventures Fund III Limited Partnership
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A Convertible Preferred Stock Acquisiton 2015-05-05 10,000,000 $0.00 1,818,181 $0.00
Common Stock Series B Convertible Preferred Stock Acquisiton 2015-05-05 2,583,333 $0.00 469,696 $0.00
Common Stock Series C Convertible Preferred Stock Acquisiton 2015-05-05 483,092 $0.00 87,834 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. On May 5, 2015, in connection with the completion of the issuer's initial public offering, all shares of Convertible Preferred Stock converted into Common Stock on a 5.5-for-1 basis.
  2. FMR Co., Inc. and Pyramis Global Advisors, LLC, each an indirect wholly-owned subsidiary of FMR LLC and an investment adviser registered under the Investment Advisers Act of 1940, and Pyramis Global Advisors Trust Company, an indirect wholly-owned subsidiary of FMR LLC and a bank as defined in Section 3(a)(6) of the Securities Exchange Act of 1934, are the beneficial owners of Common Stock of Blueprint Medicines Corp., as a result of acting as investment adviser to various investment companies registered under the Investment Company Act of 1940, institutional accounts and non-U.S. mutual funds. FMR LLC, Edward C. Johnson 3d and Abigail P. Johnson have no pecuniary interest in the Common Stock beneficially owned by FMR Co., Inc. and Pyramis Global Advisors, LLC and Pyramis Global Advisors Trust Company and Column 5 of Table I does not include such shares.